Skip to main content
 

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

Accept

Home

 

We are passionate about applying cutting-edge science
to the development of life-changing therapies. Cancer has no borders. Neither do we.

Our Story Pipeline

 
  • BeiGene Facts
  • Founded 2010
  • Listings NASDAQ: BGNE   HKEX: 06160
  • Internally Developed
    Clinical Candidates 6
  • Marketed Products

    in China 3
  • Global Team 1700+
About
 

About Us

A Business
Approach that Looks Beyond Borders

We are becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.

About Us

Science
 

Our Expertise

Cancer is Relentless Our Scientists Are Too

We have developed broad internal capabilities utilizing rational drug design to identify and target the genes and proteins that drive cancer, as well as a unique immuno-oncology platform. Our R&D team is also exploring synergies between targeted and immuno-oncology combination therapies.

Pipeline

News

BeiGene News

  • November 16, 2018
    BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

    BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

  • November 16, 2018
    BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

    BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

  • November 15, 2018
    Priority Review Granted to BeiGene’s New Drug Applications for Zanubrutinib and Tislelizumab in China

    Priority Review Granted to BeiGene’s New Drug Applications for Zanubrutinib and Tislelizumab in China

  • November 13, 2018
    BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  • November 7, 2018
    BeiGene Initiates Global Head-to-Head Phase 3 Clinical Trial of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    BeiGene Initiates Global Head-to-Head Phase 3 Clinical Trial of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  • November 7, 2018
    BeiGene Reports Third Quarter 2018 Financial Results

    BeiGene Reports Third Quarter 2018 Financial Results

story
 
  • 2010

    • BeiGene starts as a research and development company
    BeiGene Co-Founders, John V. Oyler and Xiaodong Wang, Ph.D.
  • 2012

    • Began work on both a PD-1 antibody and a BTK inhibitor
    Immuno-oncology Therapies
  • 2014

    • Started clinical trials of pamiparib and zanubrutinib
    Clinical Researcher
  • 2016

    • Went public on the Nasdaq, with $182 million initial public offering
    First China biotech to go public on the Nasdaq
  • 2018

    • 50+ ongoing or planned clinical trials
    BeiGene expands global operations

Our Story

Breaking Boundaries From the Beginning

From our start in Beijing with a handful of scientists and developers, to today, with a global team, a rich pipeline, strong partnerships, and commercial products. We have accomplished so much in a short time, and yet there is so much still to do.

Our Story

Partnering

Partnering

Partnerships that ExtendAround the Globe

BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships

Celgene LogoMirati LogoMei Pharma

Partners

Patients
 

Our Patients

Our Commitment to
Patients

At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.

Patients

Careers
 

Careers

Join Our
Team

We’re looking for highly motivated colleagues who can collaborate with us as we build a company that will have a lasting impact on the global fight against cancer.

Careers